Limits...
SS-31 attenuates TNF-α induced cytokine release from C2C12 myotubes.

Lightfoot AP, Sakellariou GK, Nye GA, McArdle F, Jackson MJ, Griffiths RD, McArdle A - Redox Biol (2015)

Bottom Line: The aim of this study was to determine the effect of TNF-α on the production of myokines by skeletal muscle.Significant increases were seen in the release of IL-6, MCP-1/CCL2, RANTES/CCL5 and KC/CXCL1 and this release was inhibited by treatment with Brefeldin A, suggesting a golgi-mediated release of cytokines by muscle cells.The changes in superoxide, activation of NF-kB and release of myokines were attenuated following pre-treatment with SS-31 peptide indicating that the ability of TNF-α to induce myokine release may be mediated through mitochondrial superoxide, which is, at least in part, associated with activation of the redox sensitive transcription factor NF-kB.

View Article: PubMed Central - PubMed

Affiliation: MRC-Arthritis UK Centre for Integrated Research into Musculoskeletal Ageing, University of Liverpool, United Kingdom.

No MeSH data available.


Fold changes in gene expression for IL-6 (A), MCP-1/CCL2 (B), CXCL1 (C) and RANTES/CCL5 (D) in myotubes following treatment with TNF-α (25 ng/ml) with or without 1 h pre-treatment with SS31 (5 μM). Data are represented as mean fold change normalised to s29 housekeeper gene±SEM, *p<0.05 (n=4–6 in each group).
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4556772&req=5

f0010: Fold changes in gene expression for IL-6 (A), MCP-1/CCL2 (B), CXCL1 (C) and RANTES/CCL5 (D) in myotubes following treatment with TNF-α (25 ng/ml) with or without 1 h pre-treatment with SS31 (5 μM). Data are represented as mean fold change normalised to s29 housekeeper gene±SEM, *p<0.05 (n=4–6 in each group).

Mentions: Elevated and substantial changes in the expression (fold-change) of CCL2 (59.1±8.8), CXCL1 (2.1±0.35), CCL5 (137.1±24.6) were seen in myotubes following treatment with TNF-α compared with untreated cells; no change was detected in IL-6 expression (Fig. 2). Such dramatic fold-changes in mRNA were likely to be due to the very low levels of expression in untreated cells. Pre-treatment of C2C12 myotube with SS-31 peptide prior to TNF-α challenge resulted in attenuated expression of CCL2 but no effect of SS-31 was observed on the TNF-α mediated increase in mRNA for CCL5 or CXCL1 (Fig. 2).


SS-31 attenuates TNF-α induced cytokine release from C2C12 myotubes.

Lightfoot AP, Sakellariou GK, Nye GA, McArdle F, Jackson MJ, Griffiths RD, McArdle A - Redox Biol (2015)

Fold changes in gene expression for IL-6 (A), MCP-1/CCL2 (B), CXCL1 (C) and RANTES/CCL5 (D) in myotubes following treatment with TNF-α (25 ng/ml) with or without 1 h pre-treatment with SS31 (5 μM). Data are represented as mean fold change normalised to s29 housekeeper gene±SEM, *p<0.05 (n=4–6 in each group).
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4556772&req=5

f0010: Fold changes in gene expression for IL-6 (A), MCP-1/CCL2 (B), CXCL1 (C) and RANTES/CCL5 (D) in myotubes following treatment with TNF-α (25 ng/ml) with or without 1 h pre-treatment with SS31 (5 μM). Data are represented as mean fold change normalised to s29 housekeeper gene±SEM, *p<0.05 (n=4–6 in each group).
Mentions: Elevated and substantial changes in the expression (fold-change) of CCL2 (59.1±8.8), CXCL1 (2.1±0.35), CCL5 (137.1±24.6) were seen in myotubes following treatment with TNF-α compared with untreated cells; no change was detected in IL-6 expression (Fig. 2). Such dramatic fold-changes in mRNA were likely to be due to the very low levels of expression in untreated cells. Pre-treatment of C2C12 myotube with SS-31 peptide prior to TNF-α challenge resulted in attenuated expression of CCL2 but no effect of SS-31 was observed on the TNF-α mediated increase in mRNA for CCL5 or CXCL1 (Fig. 2).

Bottom Line: The aim of this study was to determine the effect of TNF-α on the production of myokines by skeletal muscle.Significant increases were seen in the release of IL-6, MCP-1/CCL2, RANTES/CCL5 and KC/CXCL1 and this release was inhibited by treatment with Brefeldin A, suggesting a golgi-mediated release of cytokines by muscle cells.The changes in superoxide, activation of NF-kB and release of myokines were attenuated following pre-treatment with SS-31 peptide indicating that the ability of TNF-α to induce myokine release may be mediated through mitochondrial superoxide, which is, at least in part, associated with activation of the redox sensitive transcription factor NF-kB.

View Article: PubMed Central - PubMed

Affiliation: MRC-Arthritis UK Centre for Integrated Research into Musculoskeletal Ageing, University of Liverpool, United Kingdom.

No MeSH data available.